Search research articles
Contact Us
Filters
Showing results (31-40 of 65) with videos related to
Page
of 7
Sort By:
The Lancet. Oncology
|
April 30, 2022
FDA decisions on new oncological drugs
David J Benjamin, Vinay Prasad, Mark P Lythgoe
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2024
Access divergence to new cancer medicines in the United Kingdom
Mark P Lythgoe, Sarah Blagden, Susannah Stanway, et al.
Journal of Cancer Policy
|
April 14, 2024
Implications of FDA's marketing authorization of hereditary cancer testing
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
JCO Oncology Practice
|
January 16, 2024
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Cancers
|
August 27, 2021
Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
Rohini Sharma, Mark P Lythgoe, Bhavandeep Slaich, et al.
JAMA Network Open
|
November 18, 2021
Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
Alyson Haslam, Mark P Lythgoe, Emma Greenstreet Akman, et al.
JAMA Network Open
|
March 15, 2022
Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
David J Benjamin, Alexander Xu, Mark P Lythgoe, et al.
Familial Cancer
|
December 1, 2017
Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis
Salim S Malik, Mark P Lythgoe, Mark McPhail, et al.
Familial Cancer
|
February 17, 2018
Response to letter to editor regarding published article-metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis
Mark P Lythgoe, Salim S Malik, Mark McPhail, et al.
Trends in Cancer
|
May 9, 2024
Lifileucel: the first cellular therapy approved for solid tumours
Max Julve, Mark P Lythgoe, James Larkin, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 65) with videos related to
Sort By:
Page
of 7
The Lancet. Oncology
|
April 30, 2022
FDA decisions on new oncological drugs
David J Benjamin, Vinay Prasad, Mark P Lythgoe
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2024
Access divergence to new cancer medicines in the United Kingdom
Mark P Lythgoe, Sarah Blagden, Susannah Stanway, et al.
Journal of Cancer Policy
|
April 14, 2024
Implications of FDA's marketing authorization of hereditary cancer testing
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
JCO Oncology Practice
|
January 16, 2024
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Cancers
|
August 27, 2021
Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
Rohini Sharma, Mark P Lythgoe, Bhavandeep Slaich, et al.
JAMA Network Open
|
November 18, 2021
Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
Alyson Haslam, Mark P Lythgoe, Emma Greenstreet Akman, et al.
JAMA Network Open
|
March 15, 2022
Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
David J Benjamin, Alexander Xu, Mark P Lythgoe, et al.
Familial Cancer
|
December 1, 2017
Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis
Salim S Malik, Mark P Lythgoe, Mark McPhail, et al.
Familial Cancer
|
February 17, 2018
Response to letter to editor regarding published article-metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis
Mark P Lythgoe, Salim S Malik, Mark McPhail, et al.
Trends in Cancer
|
May 9, 2024
Lifileucel: the first cellular therapy approved for solid tumours
Max Julve, Mark P Lythgoe, James Larkin, et al.
Page
of 7